参考文献/References:
[1]Kao JH.Hepatitis B vaccination and prevention of hepatocellular carcinoma[J].Best Pract Res Clin Gastroenterol,2015,29(6):907-917.[2]Lai CL,Yuen MF.The natural history and treatment of chronic hepatitis B:A critical evaluation of standard treatment criteria and end points[J].Ann Intern Med,2007,147(1):58-61.[3]Raimondo G,Allain JP,Brunetto M,et al.Statements from the Taormina expert meeting on occult hepatitis B virus infection[J].J Hepatol,2008,49(4):652-657. [4]Hadziyannis E,Laras A.Viral Biomarkers in Chronic HBeAg Negative HBV Infection[J].Genes,2018,9(10):469.[5]Maasoumy B,Wiegand SB,Jaroszewicz J,et al.Hepatitis B core-related antigen(HBcrAg)levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D[J].Clin Microbiol Infect,2015,21(6):606,e1-e10.[6]Lin CL,Kao JH.New perspectives of biomarkers for the management of chronic hepatitis B[J].Clin Mol Hepatol,2016,22(4):423-431.[7]Kimura T,Rokuhara A,Sakamoto Y,et al.Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load[J].J Clin Microbiol,2002,40(20):439-445.[8]Locarnini S,Zoulim F.Molecular genetics of HBV infection[J].Antivir Ther,2010,15(Suppl 3):3-14.[9]Wong DK,Seto WK,Cheung KS,et al.Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA[J].Liver Int,2017,37(7):995-1001.[10]Wong DK,Yuen MF,Yuan H,et al.Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients[J].Hepatology,2004,40(3):727-737. [11]Wang L,Cao X,Wang Z,et al.Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients[J].J Clin Microbiol,2019,57(1):e01303-e01318.[12]Hasegawa K,Nishikawa H,Enomoto H,et al.Proposed model for the prediction of intrahepatic covalently closed circular DNA level in patients with chronic hepatitis B[J].Hepatol Res,2018,49(3):271-283.[13]Seto WK,Wong DK,Fung J,et al.Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B[J].Clin Microbiol Infect,2014,20(11):1173-1180. [14]Liu YY,Liang XS.Progression and status of antiviral monitoring in patients with chronic hepatitis B:From HBsAg to HBV RNA[J].World J Hepatol,2018,10(9):603-611.[15]Chen EQ,Wang ML,Tao YC,et al.Serum HBcrAg is better than HBV RNA and HBsAg in reflflecting intrahepatic covalently closed circular DNA[J].J Viral Hepat,2019,26(5):586-595.[16]Suzuki Y,Maekawa S,Komatsu N,et al.HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers[J].PLoS One,2019,14(2):e0212559. [17]Suzuki F,Miyakoshi H,Kobayashi M,et al.Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients[J].J Med Virol,2009,81(1):27-33.[18]Misawa N,Matsumoto A,Tanaka E,et al.Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics[J].J Med Virol,2006,78(1):68-73.[19]Seto WK,Wong DK,Fung J,et al.Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B[J].Clin Microbiol Infect,2014,20(11):1173-1180.[20]Testoni B,Lebosse F,Scholtes C,et al.Serum hepatitis B core-related antigen(HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients[J].J Hepatol,2019,70(4):615-625.[21]Zhang ZQ,Lu W,Wang YB,et al.Measurement of the hepatitis B core-related antigen is valuable for predicting the pathological status of liver tissues in chronic hepatitis B patients[J].J Virol Methods,2016,235:92-98. [22]Loggi E,Vukotic R,Conti F,et al.Serum hepatitis B core-related antigen is an effffective tool to categorize patients with HBeAg-negative chronic hepatitis[J].B J Viral Hepat,2019,26(5):568-575.[23]Seto WK,Tanaka Y,Wong DK,et al.Evidence of serologic activity in chronic hepatitis B after surface antigen(HBsAg)seroclearance documented by conventional HBsAg assay[J].Hepatol Int,2012,7(1):98-105. [24]Jeng WJ,Chen YC,Sheen IS,et al.Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients[J].Clin Gastroenterol Hepatol,2016,14(12):1813-1820.[25]JSH Guidelines for the Management of Hepatitis B Virus Infection[J].Hepatol Res,2014,44 (Suppl.S1):1-58.[26]Lai CL,Wong D,Ip P,et al.Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B[J].J Hepatol,2017,66(2):275-281.[27]Lutgehetmann M,Volzt T,Quaas A,et al.Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication[J].Antivir Ther,2008,13(1):57-66.[28]Wong DK,Tanaka Y,Lai CL,et al.Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection[J].J Clin Microbiol,2007,45(12):3942-3947. [29]Chuaypen N,Posuwan N,Payungporn S,et al.Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B[J].Liver Int,2016,36(6):827-836.[30]Matsumoto A,Yatsuhashi H,Nagaoka S,et al.Factors associated with the effffect of interferon-alpha sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B[J].Hepatol Res,2015,45(12):1195-1202.[31]Tanaka E,Matsumoto A,Suzuki F,et al.Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance[J].Liver Int,2006,26(1):90-96.[32]Wang B,Carey I,Bruce M,et al.HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues[J].J Viral Hepat,2018,25(8):886-893. [33]Caviglia GP,Abate ML,Noviello D,et al.Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-alpha[J].Hepatol Res,2017,47(8):747-754. [34]Jung KS,Park JY,Chon YE,et al.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients[J].J Gastroenterol,2016,51(8):830-839.[35]Matsumoto A,Tanaka E,Minami M,et al.Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy[J].HepatolRes,2007,37(8):661-666.[36]Shinkai N,Tanaka Y,Orito E,et al.Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection[J].Hepatol Res,2006,36(4):272-276.[37]Hsu YC,Nguyen MH,Mo LR,et al.Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk[J].Aliment Pharmacol Ther,2019,49(1):107-115.[38]Ganem D,Prince AM.Hepatitis B virus infection–natural history and clinical consequences[J].N Engl J Med,2004,350(11):1118-1129. [39]Liu S,Zhou B,Valdes JD,et al.Serum HBV RNA:A New Potential Biomarker for Chronic Hepatitis B Virus Infection[J].Hepatology,2019,69(4):1816-1827.[40]Schadler S,Hildt E.HBV life cycle:Entry and morphogenesis[J].Viruses,2009,1(2):185-209. [41]Misawa N,Matsumoto A,Tanaka E,et al.Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics[J].Journal of Medical Virology,2010,78(1):68-73.[42]Honer Zu Siederdissen C,Maasoumy B,Cornberg M.What is new on HBsAg and other diagnostic markers in HBV infection Best Pract[J].Res Clin Gastroenterol,2017,31(3):281-289.[43]Liu YY,Liang XS.Progression and status of antiviral monitoring in patients with chronic hepatitis B:From HBsAg to HBV RNA[J].World J Hepatol,2018,10(9):603-611.